Clorox (CLX) Q1 2027 Earnings Call Transcript

Clorox reported fiscal Q1 net sales of $1.91 billion, up 33% year over year, and adjusted EPS of $1.55, up 82%; growth included a 15-point contribution from GOJO and benefited from comparison with the prior-year ERP-related inventory drawdown. The company expects $240 million of fiscal-year input cost inflation—$40 million more than previously expected and about 2.5 times its historical annual average—while forecasting organic sales growth of 3.5%–4.5% and adjusted EPS of $5.70–$6.00. Gross margin fell 130 basis points to 40.4%, and full-year gross margin guidance is 41.5%; management cited productivity, targeted pricing and GOJO synergies as mitigation, while noting persistent cost uncertainty. Fabian Garcia will succeed Linda Rendle as CEO effective Jan. 5, 2027.

Analysis

The headline growth rate overstates the underlying demand signal: once the ERP comparison is removed, management’s own outlook implies only flat-to-1% organic growth. That makes the investment case hinge on converting share gains and late-year innovation into durable consumption—not on reported sales growth. Meanwhile, inflation arrives in the P&L before targeted pricing and productivity fully catch up, so the near-term risk is margin disappointment even if full-year guidance holds. Glad’s resin exposure makes further price actions logical, but value-seeking consumers and weak Litter share limit confidence that pricing can be broad without volume trade-offs.

The second-order opportunity is operational rather than immediate: ERP optimization and GOJO integration could expand productivity over several years, but management’s synergy confidence is not yet proof of incremental earnings quality. Verify realized savings, cash conversion, and segment-level margins before capitalizing the pipeline. The CEO handoff in January adds execution risk just as back-half innovation and margin recovery are expected to carry the year.

Near term (days to weeks), the reported beat may support sentiment, but it is not a clean demand re-rating. Over 1–3 months, watch consumption versus shipments, pricing pass-through, and gross-margin delivery; the company’s stated cost visibility is limited. Over 6–18 months, ERP benefits and GOJO synergies could improve the margin profile, while persistent resin, transport, or commodity inflation could absorb those gains. The contrarian risk is that investors either over-credit the ERP lap as real growth or dismiss the productivity engine too quickly. Falsify the cautious view if underlying consumption turns sustainably positive and margins recover without material share loss; reinforce it if guidance is cut, Litter weakness persists, or pricing produces volume deterioration.

Key Decisions for Investors

• Do not chase CLX on reported growth alone; treat the ERP-adjusted demand trajectory as the relevant baseline until consumption confirms acceleration.
• For a 1–3 month relative-value stance, underweight or short CLX against a diversified consumer-staples exposure rather than making a large outright short: the margin/pricing lag is a headwind, but productivity and GOJO integration are credible offsets. Reassess after the next report.
• Track quarterly gross margin, organic sales excluding ERP effects, retail consumption versus shipments, and realized GOJO synergies. A margin recovery accompanied by stable or improving consumption would invalidate the cautious stance.
• Keep a watch item on resin and transportation costs and on pricing pass-through: broad-based cost persistence or volume declines after price actions would raise downside risk; no specific options trade is warranted without valuation and implied-volatility context.